Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
The complex problems associated with antimicrobial resistance and the hurdles to overcoming the crisis are well known, and there is no lack of plans and strategies to tackle the situation. Yet, ‘superbugs’ are on the rise and spread fast. So, what does it take to tackle the antimicrobial resistance crisis? What is needed are global leadership and bold steps from policymakers and the industry to make headway. This new Collection comprises Review, Viewpoint and Comment articles that highlight how the global scientific and public health communities as well as governmental and regulatory bodies focus on key areas to address the threat posed by antimicrobial resistance.
Over the past decade, Klebsiella pneumoniae has emerged as a major clinical and public health threat. In this Review, Wyres, Lam and Holt discuss how genomics approaches have advanced our understanding of K. pneumoniae taxonomy, ecology and evolution as well as the diversity and distribution of clinically relevant determinants of pathogenicity and antimicrobial resistance.
In this Review, Berman and Krysan define and distinguish resistance and tolerance, and discuss the current understanding of the molecular, genetic and physiological mechanisms that contribute to those phenomena. Distinguishing tolerance from resistance might provide important insights into the reasons for treatment failure in some settings.
In this Review, van Belkum and colleagues discuss routinely used antimicrobial susceptibility testing (AST) methods, explore current efforts to improve phenotypic AST systems — including new emerging technologies as well as genomic and gene-based antimicrobial resistance detection methods — and highlight the challenges and opportunities for new rapid AST systems.
With rising rates of antibiotic resistance, it is essential that new antibiotics are developed. In this Review, Theuretzbacher et al. take stock of the preclinical antibiotic pipeline and discuss challenges and opportunities for the discovery and development of novel antibacterial therapies.
New antibacterial agents are urgently needed to address the global increase in resistance. In this Review, Theuretzbacher and colleagues critically review the current published literature and publicly available information on antibacterial agents in all phases of clinical development.
In this Viewpoint article, seven experts discuss the challenges that are contributing to the decline in antibiotic drug discovery and development, and the international and national initiatives aimed at incentivizing research and the development of new antibiotics to improve the economic feasibility of antibiotic development.
To control antimicrobial resistance (AMR) will require approaches to develop, share and preserve antibiotics that are scaled to the scientific, economic and ethical dimensions of the crisis. The three cooperative, interdisciplinary, international councils proposed in this Comment by Carl Nathan exemplify what this will require.
Resistance to the current first-line antimalarials threatens the control of malaria caused by Plasmodium falciparum and underscores the urgent need for new drugs with novel modes of action. Small-Saunders, Hagenah and Fidock present the argument that the parasite’s chloroquine resistance transporter (PfCRT) constitutes a promising target to combat multidrug-resistant malaria.